U.S. Hotel and Resort REITs Stock News

Willdan Group stock jumped 17% to US$86.24 after its Q2 print, and for once the emotion lines up with the numbers. This is a sentiment reset driven by earnings power. Contract revenue reached US$231.0m and basic earnings per share hit US$1.62, while adjusted EBITDA margins for the quarter stood in the high 20s. For an engineering and energy efficiency specialist that lives and dies on project execution and profitability, this margin step up is the headline. The rest of the report fills in how...

IonQ (NYSE: IONQ) subsidiary Capella secured a significant National Reconnaissance Office Radar Commercial Augmentation contract for commercial SAR data. The award expands IonQ's role in supplying mission critical data and services to U.S. national security and defense customers. The NRO contract adds a new national security oriented revenue stream alongside IonQ's existing government and commercial engagements. This move highlights how quantum and adjacent space data services are starting...

American Realty Investors shares edged 2.5% higher to US$15.36 after the Q2 release, even though the headline story was fresh pressure on profitability. The stock came into earnings after a weak 30 day stretch, and traders quickly focused on the company’s still positive trailing 12 month earnings. The real tension is between that profitable trailing picture and the quarterly income statement, which showed a small loss alongside modest revenue of US$12.9m. With a P/E of 29.7x, sitting above...

Koppers Holdings stock came into this earnings print with a strong three month run, then slipped about 2% to close near US$51 after the report. That small pullback sits awkwardly against the headline number. The company booked Q2 revenue of US$520.1m but reported a sharp quarterly loss, driven by heavy charges tied to accelerating the shutdown of its Stickney facility. The real story for you is not the one day move. It is the margin pressure from cost inflation and the balance sheet strain...

Advanced Drainage Systems dropped about 3% today, which looks odd when you line it up against what just happened in the business. The stock came into this earnings print after a flat month and a modest gain over the past quarter. Yet the company just booked roughly US$1.0b in quarterly revenue and one of its highest ever adjusted earnings before interest, tax, depreciation and amortization margins at 35.8%. The short term mood is cautious. The longer term story is that Advanced Drainage...

Novavax stock inched up about 3% to US$7.95 into the Q2 print, a modest move for a biotech that just posted another quarterly loss. The headline this quarter is not the loss itself. It is the pressure on the income statement as revenue for Q2 came in at US$56.7m and net loss reached US$53.4m. In the very short term traders are reacting to that mix of revenue and red ink. Long term holders are more likely focused on the gap between the current P/S multiple and valuation models that point to a...

Elevance Health stock has delivered a strong 36.9% return over the past year, and the current valuation checks now raise the question of whether that strength is still backed by a discount or already reflected in the price. Over the last 12 months, Elevance Health is up 36.9%, which puts recent buyers in a comfortable position and makes entry price more important for anyone considering the stock today. The company’s push to strengthen its connected cancer care model can support longer term...

Intellia Therapeutics stock jumped 6.2% to US$11.94 after earnings, which suggests investors heard something they liked from a gene editing story that has delivered sharp volatility in recent months. The headline is simple: the science stepped forward while the income statement stayed firmly in loss-making territory. Q2 revenue came in at US$7.7m and Intellia reported a net loss of US$106.6m. The cash pile of US$628.4m and management’s stated runway into at least 2028 now sit at the center of...

Equity Bancshares buyback puts focus on capital return and valuation Equity Bancshares (EQBK) has announced a one year share repurchase program covering up to 1,000,000 shares of its outstanding common stock, prompting fresh attention on how the bank is choosing to deploy capital. See our latest analysis for Equity Bancshares. At a share price of US$50.94, Equity Bancshares has seen a 30 day share price return of 6.64% and a year to date share price return of 13.55%, while its 1 year total...

PRA Group stock jumped 9% to US$19.79 after the Q2 release, a sharp move for a consumer finance recovery specialist that has spent the past year in the red on a trailing basis. Traders reacted to one clear headline: core collections and balance sheet economics point to a rebuilding earnings engine, with Q2 net income of US$57.9m and basic earnings per share of US$1.52. The short term pop matters if you are trading the chart. The bigger story is whether this quarter marks the first credible...

Emergent BioSolutions came into this earnings print as a beaten down biotech, with the stock already down sharply over the past three months and now dropping another 8.9% to about US$4.84 after the release. The headline is not the top line. Q2 revenue of US$234.3m and adjusted EBITDA strength from its Medical Countermeasures business landed against a stark reality on the income statement. The company reported a Q2 net loss of US$180.2m, driven in large part by a large non cash impairment tied...

Genie Energy came into this earnings print on a quiet upswing, with the stock up over the past week and month, only to slip about 1.3% to US$14.55 after the release. That small pullback hides the real headline. Profitability snapped sharply higher in Q2, with net income excluding extra items at US$11.4m and basic earnings per share at US$0.44, even on softer revenue of about US$100.4m. The story today is margin power returning to a retail energy and renewables business that had been marked by...

What Sanmina’s Latest Earnings Mean For Investors Sanmina (SANM) has stepped into the spotlight after reporting third quarter sales of US$3.46b and net income of US$117.13m, alongside raised full year revenue guidance and inclusion in the Zacks Rank #1 growth stocks list. These updates provide fresh data points that investors can use to assess whether the recent share performance and current valuation align with the company’s earnings profile and growth characteristics. See our latest...

Red Cat Holdings stock jumped 6.2% to US$9.21 into the first full session after earnings, yet the mood around the stock is anything but relaxed. Traders are cheering the aerospace and defense drone specialist for one headline figure. Quarterly revenue landed at US$20.2m, with reported gross margin at 16.1%, which stands out in a sector where volume and unit economics can quickly swing sentiment. The catch is that Red Cat Holdings is still posting sizeable net losses and carries a rich P/S...

Verastem walked into this earnings print with a stock that had already been heating up, yet the market still punched the gas. Shares jumped about 14% to US$6.74 after the Q2 release. That kind of move in a volatile biotech usually signals investors see something more durable than a one quarter bump. The headline is clear for Verastem. Product revenue in Q2 reached about US$25.1m and total revenue for the quarter was a little over US$40m, while the company still reported a sizeable net loss...

ATI shareholders woke up to a 2% gain today, which looks modest compared with the strength of the latest aerospace heavy earnings print. The stock comes into this report already riding sharp momentum over the past quarter, yet the market reaction still feels restrained, given a headline quarter built on higher revenue of about US$1.3b and a clear jump in basic earnings per share. The real story is margin power. Adjusted EBITDA of US$284m and a 22.6% margin in Q2 turned ATI’s long running...

Tariff refunds worth an estimated $100b are now flowing back to giants like Apple, Ford and Amazon after the Supreme Court overturned parts of the Trump era trade policy. Some companies are signalling they will share at least some of the savings with shoppers. Others are keeping quiet. For investors, that mix of legal rulings, policy uncertainty and possible pricing shifts creates fresh openings. This article walks through 3 large cap consumer and retail stocks from the screener that stand...

The market shrugged off Liberty Live Holdings' latest quarter with a mild 0.9% slide, but the earnings story is far louder than that single day move suggests. This stock has been priced as a high growth entertainment play, yet Q2 still rested on heavy losses and a stretched valuation. Liberty Live reported Q2 revenue of US$147.1m alongside a net loss of US$268.7m, keeping earnings per share deep in the red. With a P/S multiple around 26x compared with much lower industry levels, the results...

GigaCloud Technology stock barely flinched after earnings, up about 1.6% to US$53.25, even though the report highlighted clear top line and profit strength. Revenue for Q2 landed at about US$411.6m with net income of US$42.3m, and the company stayed debt free with US$379m of liquidity. The muted one day move suggests investors treated this as confirmation rather than a fresh catalyst. With trailing P/E near 12.5x and a buyback program in place, the market reaction points more to cautious...

TriSalus Life Sciences just jumped 15.2% to US$5.61, yet the quarter itself reads more like a profitability reset than a clean win. The stock had already been on a strong run over the past month, so this move reflects relief as much as excitement. The headline is simple: Q2 revenue reached US$11.4m and gross margin sat at a high 86.8%, but TriSalus reported a net loss of US$9.2m and a wider adjusted EBITDA loss of about US$7.1m as sales and marketing spending climbed. The real story is the...

Ryman Hospitality Properties shares slipped about 3% to US$120.84 after the Q2 release, even though the core real estate metric told a stronger story. Funds From Operations, the key cash flow gauge for a hotel and resort REIT, reached US$143.5 million in Q1 and was more than US$510 million on a trailing twelve month basis. Revenue for Q2 was US$748.9 million. The short term price weakness contrasts with a company generating substantial cash flow, which keeps attention on how investors weigh...

Cars.com stock jumped about 5% to US$12.32 after its Q2 2026 report, a strong move for a business that has mostly traded in a lower gear this year. The immediate spark is clear. Earnings per share climbed to about US$0.26 and adjusted earnings before interest, tax, depreciation and amortization margin held near 29%. The short term story is a relief rally. The longer term question is whether a company with only modest revenue growth and a sizeable gap to a discounted cash flow estimate can...

CytomX Therapeutics stock edged up about 3% to US$3.46 into this post earnings lull, even though the headline numbers lean more sobering than celebratory. Quarterly revenue came in at US$1.4 million and the company reported a net loss of US$20.7 million, which keeps the long running profitability debate very much alive. The real focus is the contrast between a modest one day bounce and a business model that still leans heavily on future drug success and an already rich P/S multiple. The...

Relay Therapeutics stock barely budged after earnings, ticking up just 0.1% to US$19.77, yet the results point to a much tougher story than the price suggests. Revenue for the quarter came in at only US$0.35 million, while the company reported a net loss of US$83.7 million. For a high risk biotech that depends on future potential, the central issue is the persistent cash burn and a price to book ratio above the broader biotech industry. Short term traders see a flat day. Long term holders may...